Cefoperazone/Sulbactam-Induced Abdominal Wall Hematoma and Upper Gastrointestinal Bleeding: A Case Report and Review of the Literature

ZhuYing Cai, Wei Yang, YingYing He, Qingge Chen, ShiQiang Wang, Xuming Luo, Xiongbiao Wang, ZhuYing Cai, Wei Yang, YingYing He, Qingge Chen, ShiQiang Wang, Xuming Luo, Xiongbiao Wang

Abstract

An 87-year-old woman developed abdominal wall hematoma and upper gastrointestinal bleeding during treatment with cefoperazone/sulbactam for pneumonia. The woman received cefoperazone/sulbactam at 4.5 g twice daily for intravenous infusion. After 7 days, she developed sudden onset of left lower abdominal pain, associated with subcutaneous mass, and vomited a coffee-colored liquid. Investigations revealed a coagulation index abnormality and activated partial thromboplastin time and prothrombin time increased obviously. She was diagnosed with cefoperazone-induced hemorrhage. Cefoperazone/sulbactam was discontinued and the patient received vitamin K1. The blood coagulation function improved and hematoma disappeared after 3 days. A Naranjo assessment score of 6 was obtained, indicating a probable relationship between the patient's coagulation function disorder and her use of the suspect drug.

Conflict of interest statement

Compliance with Ethical Standards Conflicts of interest ZhuYin Cai, Wei Yang, YingYing He, Qingge Chen, ShiQiang Wang, Xuming Luo and Xiongbiao Wang declare that they have no conflict of interest. Consent Written informed consent was obtained from the patient for publication of this case report and the accompanying images. A copy of the written consent may be requested for review from the corresponding author.

Figures

Fig. 1
Fig. 1
a Hematoma at lower left abdominal wall was suggested by abdominal CT. b Mixed masses at left lower abdominal wall was revealed by the abdomen B ultrasound. c Absorbed hematoma by B ultrasound

References

    1. Cohen MS, Washton HE, Barranco SF. Multicenter clinical trial of cefoperazone sodium in the United States. Am J Med. 1984;77(1B):35–41. doi: 10.1016/S0002-9343(84)80094-7.
    1. Bailey RR, Peddie B, Blake E, Bishop V, Reddy J. Cefoperazone in the treatment of severe or complicated infections. Drugs. 1981;22(Suppl 1):76–86. doi: 10.2165/00003495-198100221-00017.
    1. Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev. 2010;23(1):160–201. doi: 10.1128/CMR.00037-09.
    1. Greenberg RN, Reilly PM, Weinandt WJ, Bollinger M, Kennedy DJ. Cefoperazone-sulbactam combination in the treatment of urinary tract infections: efficacy, safety, and effects on coagulation. Clin Ther. 1987;10(1):52–56.
    1. Koga H, Tomono K, Hirakata Y, Kohno S, Abe K, Kawamoto S, et al. Clinical evaluation of sulbactam/cefoperazone for lower respiratory tract infections. Correlation between the efficacy of sulbactam/cefoperazone and beta-lactamase. Jpn J Antibiot. 1996;49(8):800–807.
    1. Li JT, Lu Y, Hou J, Chen YF, Miao JZ, Jia YX, et al. Sulbactam/cefoperazone versus cefotaxime for the treatment of moderate-to-severe bacterial infections: results of a randomized, controlled clinical trial. Clin Infect Dis Off Publ Infect Dis Soc Am. 1997;24(3):498–505. doi: 10.1093/clinids/24.3.498.
    1. Xin X, Jian L, Xia X, Jia B, Huang W, Li C, et al. A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/sulbactam in the treatment of respiratory and urinary tract infections. Ann Clin Microbiol Antimicrob. 2013;12:38. doi: 10.1186/1476-0711-12-38.
    1. Andrassy K, Koderisch J, Fritz S, Bechtold H, Sonntag H. Alteration of hemostasis associated with cefoperazone treatment. Infection. 1986;14(1):27–31. doi: 10.1007/BF01644806.
    1. Islek I, Baris S, Katranci AO, Ariturk E, Gurses N. Hypersensitivity vasculitis induced by cefoperazone/sulbactam. Ann Clin Microbiol Antimicrob. 2003;3(2):1. doi: 10.1186/1476-0711-2-1.
    1. Mitra S, Basu S. Cefoperazone/sulbactam induced hyponatremia. Indian J Med Sci. 2006;60(4):158–159. doi: 10.4103/0019-5359.24680.
    1. Alagozlu H, Cindoruk M, Unal S. Severe INR elevation in a patient with choledocholithiasis receiving cefoperazone. Clin Drug Investig. 2006;26(8):481–484. doi: 10.2165/00044011-200626080-00006.
    1. Alitalo R, Ruutu M, Valtonen V, Lehtonen T, Pentikainen PJ. Hypoprothrombinaemia and bleeding during administration of cefamandole and cefoperazone. Report of three cases. Ann Clin Res. 1985;17(3):116–119.
    1. Cristiano P. Hypoprothrombinemia associated with cefoperazone treatment. Drug Intell Clin Pharm. 1984;18(4):314–316.
    1. Strom BL, Schinnar R, Gibson GA, Brennan PJ, Berlin JA. Risk of bleeding and hypoprothrombinaemia associated with NMTT side chain antibiotics: using cefoperazone as a test case. Pharmacoepidemiol Drug Saf. 1999;8(2):81–94. doi: 10.1002/(SICI)1099-1557(199903/04)8:2<81::AID-PDS411>;2-G.
    1. Sattler FR, Weitekamp MR, Ballard JO. Potential for bleeding with the new beta-lactam antibiotics. Ann Intern Med. 1986;105(6):924–931. doi: 10.7326/0003-4819-105-6-924.
    1. Schentag JJ, Welage LS, Grasela TH, Adelman MH. Determinants of antibiotic-associated hypoprothrombinemia. Pharmacotherapy. 1987;7(3):80–86. doi: 10.1002/j.1875-9114.1987.tb03522.x.
    1. Allison PM, Mummah-Schendel LL, Kindberg CG, Harms CS, Bang NU, Suttie JW. Effects of a vitamin K-deficient diet and antibiotics in normal human volunteers. J Lab Clin Med. 1987;110(2):180–188.
    1. Schentag JJ, Welage LS, Williams JS, Wilton JH, Adelman MH, Rigan D, et al. Kinetics and action of N-methylthiotetrazole in volunteers and patients. Population-based clinical comparisons of antibiotics with and without this moiety. Am J Surg. 1988;155(5A):40–44. doi: 10.1016/S0002-9610(88)80210-1.
    1. Schafer H, Naber K, Adam D. Hemostasis disturbance caused by cephalosporins with an N-methylthiotetrazole side chain. A randomized pilot study. Arzneimittelforschung. 1989;39(9):1156–1162.
    1. Sattler FR, Colao DJ, Caputo GM, Schoolwerth AC. Cefoperazone for empiric therapy in patients with impaired renal function. Am J Med. 1986;81(2):229–236. doi: 10.1016/0002-9343(86)90256-1.
    1. Rockoff SD, Blumenfrucht MJ, Irwin RJ, Jr, Eng RH. Vitamin K supplementation during prophylactic use of cefoperazone in urologic surgery. Infection. 1992;20(3):146–148. doi: 10.1007/BF01704604.
    1. Pegram PS, Phair JP, McMahan R, Murphy RL, Gordon LI, Washton H, et al. Prospective comparative trial of short course (four day) and continuous tobramycin in combination with cefoperazone or mezlocillin in febrile, granulocytopenic patients. J Antimicrob Chemother. 1989;24(4):591–604. doi: 10.1093/jac/24.4.591.
    1. Mueller RJ, Green D, Phair JP. Hypoprothrombinemia associated with cefoperazone therapy. South Med J. 1987;80(11):1360–1362. doi: 10.1097/00007611-198711000-00007.
    1. Shimada K, Matsuda T, Inamatsu T, Urayama K. Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics. J Antimicrob Chemother. 1984;14(Suppl B):325–330. doi: 10.1093/jac/14.suppl_B.325.
    1. Weitekamp MR, Caputo GM, Al-Mondhiry HA, Aber RC. The effects of latamoxef, cefotaxime, and cefoperazone on platelet function and coagulation in normal volunteers. J Antimicrob Chemother. 1985;16(1):95–101. doi: 10.1093/jac/16.1.95.
    1. Shenkenberg TD, Mackowiak PA, Smith JW. Coagulopathy and hemorrhage associated with cefoperazone therapy in a patient with renal failure. South Med J. 1985;78(4):488–489. doi: 10.1097/00007611-198504000-00035.
    1. Freedy HR, Jr, Cetnarowski AB, Lumish RM, Schafer FJ. Cefoperazone-induced coagulopathy. Drug Intell Clin Pharm. 1986;20(4):281–283.
    1. Jones PG, Strother SV, Rolston KV, Fainstein V, Bodey GP. Hypoprothrombinemia in patients with cancer receiving cefoperazone and mezlocillin. Arch Intern Med. 1986;146(7):1397–1399. doi: 10.1001/archinte.1986.00360190183025.
    1. Guyot L, Allouch P, Fabre JP, Kazmierczak A. Prophylactic antibiotherapy in biliary surgery, cefazolin versus cefoperazone. Randomized comparative open study in a population at risk for infection. Pathologie-biologie. 1987;35(5):661–664.
    1. Muller EL, Pitt HA, Thompson JE, Jr, Doty JE, Mann LL, Manchester B. Antibiotics in infections of the biliary tract. Surg Gynecol Obstet. 1987;165(4):285–292.
    1. Mangi RJ, Greco T, Ryan J, Thornton G, Andriole VT. Cefoperazone versus combination antibiotic therapy of hospital-acquired pneumonia. Am J Med. 1988;84(1):68–74. doi: 10.1016/0002-9343(88)90010-1.
    1. Mortimer J, Miller S, Black D, Kwok K, Kirby WM. Comparison of cefoperazone and mezlocillin with imipenem as empiric therapy in febrile neutropenic cancer patients. Am J Med. 1988;85(1A):17–20. doi: 10.1016/0002-9343(88)90170-2.
    1. Royer JM, Freysz M, Sgro C, Dupont G, Honnart D. Prolonged bleeding time in 2 patients with acute renal insufficiency during treatment with cefoperazone (2nd generation cephalosporin) Therapie. 1988;43(6):485–488.
    1. Jones P, Bodey GP, Rolston K, Fainstein V, Riccardi S. Cefoperazone plus mezlocillin for empiric therapy of febrile cancer patients. Am J Med. 1988;85(1A):3–8. doi: 10.1016/0002-9343(88)90168-4.
    1. Winston DJ, Ho WG, Bruckner DA, Champlin RE. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med. 1991;115(11):849–859. doi: 10.7326/0003-4819-115-11-849.
    1. Narumi S, Sasaki M, Okudera D, Tann E, Konn M. Postoperative abnormal prothrombinemia in patients with cefoperazone: report of two cases. Surg Today. 1998;28(2):227–230. doi: 10.1007/s005950050113.
    1. Wong RS, Cheng G, Chan NP, Wong WS, Ng MH. Use of cefoperazone still needs a caution for bleeding from induced vitamin K deficiency. Am J Hematol. 2006;81(1):76. doi: 10.1002/ajh.20449.
    1. Ozen IO, Moralioglu S, Karabulut R, Bagbanci B, Turkyilmaz Z, Demirogullari B, et al. Cefoperazone induced gastro-intestinal haemorrhage. A case report. Acta Chirurgica Belgica. 2008;108(6):777–778. doi: 10.1080/00015458.2008.11680339.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren